Different rates of CD4+and CD8+T-cell proliferation in interleukin-2-treated human immunodeficiency virus-positive subjects

被引:14
作者
Caggiari, L [1 ]
Zanussi, S [1 ]
Crepaldi, C [1 ]
Bortolin, MT [1 ]
Caffau, C [1 ]
D'Andrea, M [1 ]
De Paoli, P [1 ]
机构
[1] IRCCS, Div Microbiol Immunol & Virol, Ctr Riferimento Oncol, I-33081 Aviano, Italy
来源
CYTOMETRY | 2001年 / 46卷 / 04期
关键词
HIV; CD4; CD8; Ki67; IL-2; therapy;
D O I
10.1002/cyto.1132
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Interleukin-2 (IL-2) has been used successfully to increase CD4 cell counts in patients who are human immunodeficiency virus (HIV) positive. The mechanisms involved in this phenomenon are unknown. We hypothesized that a differential proliferation rate of CD4+ compared with CD8+ lymphocytes could be related to the increase of CD4 counts and of CD4/CD8 ratios that occur in HIV+ patients during IL-2 treatment. Methods: We enrolled in our study 14 HIV+ patients treated with IL-2 or with highly active antiretroviral therapy (HAART) during a 96-week observation period. Using flow cytometry, we measured longitudinally the expression of the Ki67 antigen in peripheral blood CD4+ and CD8+ lymphocyte subsets. Results. Compared with HAART alone, IL-2 produced a rapid increase of Ki67+ proliferating CD4 cells and a concomitant increase of the CD4/CD8 ratios, whereas the corresponding CD8 proliferation increased slightly. On the contrary, HAART alone was effective in suppressing equally both CD4 and CD8 proliferation. Conclusions: Our results suggest a selective activity of IL-2 on CD4 T-cell proliferation; on the contrary, CD8-specific proliferation is affected minimally during treatment. This information may offer the potential to plan correctly immune activating regimens. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:233 / 237
页数:5
相关论文
共 26 条
[1]   Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load [J].
Arnó, A ;
Ruiz, L ;
Juan, M ;
Jou, A ;
Balagué, M ;
Zayat, MK ;
Marfil, S ;
Martínez-Picado, J ;
Martínez, MA ;
Romeu, J ;
Pujol-Borrell, R ;
Lane, C ;
Clotet, B .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :56-60
[2]  
CAGGIARI I, 2001, IN PRESS EUR CYTOMET
[3]   Effects of therapy with highly active anti-retroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients [J].
Caggiari, L ;
Zanussi, S ;
Bortolin, MT ;
D'Andrea, M ;
Nasti, G ;
Simonelli, C ;
Tirelli, U ;
De Paoli, P .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 120 (01) :101-106
[4]  
*CTR DIS CONTR, 1992, MMWR-MORBID MORTAL W, V4, P1
[5]  
Davey RT, 1997, J INFECT DIS, V175, P781, DOI 10.1086/513971
[6]   Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV plus subjects [J].
De Paoli, P ;
Zanussi, S ;
Simonelli, C ;
Bortolin, MT ;
D'Andrea, M ;
Crepaldi, C ;
Talamini, R ;
Comar, M ;
Giacca, M ;
Tirelli, U .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2737-2743
[7]  
DEPAOLI P, IN PRESS CLIN DIAG L
[8]   Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease [J].
Emery, S ;
Capra, WB ;
Cooper, DA ;
Mitsuyasu, RT ;
Kovacs, JA ;
Vig, P ;
Smolskis, M ;
Saravolatz, LD ;
Lane, HC ;
Fyfe, GA ;
Curtin, PT .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (02) :428-434
[9]   IMMUNOPATHOGENIC MECHANISMS IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) INFECTION [J].
FAUCI, AS ;
SCHNITTMAN, SM ;
POLI, G ;
KOENIG, S ;
PANTALEO, G .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (08) :678-693
[10]   Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs [J].
Fraser, C ;
Ferguson, NM ;
Ghani, AC ;
Prins, JM ;
Lange, JMA ;
Goudsmit, J ;
Anderson, RM ;
de Wolf, F .
AIDS, 2000, 14 (06) :659-669